Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersGynecologic Oncology Physician in Camden, NJ
NPI: 1326144940Primary Practice Location
COOPER UNIVERSITY HOSPITAL
1 Cooper Plz, Camden, NJ
Primary Employer
Redeemer Cancer Care Physicians Network, LLC
redeemerhealth.org
HQ Phone
Get M.D. David's Phone NumberMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
NJ State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 60 | 77 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 51 | 51 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 47 | 61 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 35 | 40 |
| 5 | 58571Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | 26 | 26 |
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.
Authors: Albert Bonebrake, Lainie Martin, Stephen Rose, Lisa Landrum, Lois Ramondetta
Publication Date: 2012-07-20
Authors: Nitika Thawani, Summer Dewdney, Jayanthi Lea, Bradley Monk, Floortje Backes, Mario Leitao, Ahmed Elsayed, Paul Disilvestro, Ivy Wilkinson-Ryan, Mark Shahin
Journal: Gynecol Oncol
Publication Date: 2025-03-07
Lead Sponsor: Imunon
Intervention / Treatment: DRUG: Carboplatin, DRUG: Paclitaxel, BIOLOGICAL: IMNN-001
Lead Sponsor: Agenus Inc.
Collaborators: GOG Foundation
Intervention / Treatment: DRUG: AGEN2034, DRUG: AGEN1884
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, RADIATION: External Beam Radiation Therapy, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, PROCEDURE: Computed Tomography, PROCEDURE: X-Ray Imaging, RADIATION: Brachytherapy
